A carregar...
Engineering less immunogenic and antigenic FVIII proteins
The development of neutralizing antibodies against blood coagulation factor VIII (FVIII), referred to clinically as “inhibitors”, is the most challenging and deleterious adverse event to occur following intravenous infusions of FVIII to treat hemophilia A. Inhibitors occlude FVIII surfaces that must...
Na minha lista:
| Publicado no: | Cell Immunol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5289291/ https://ncbi.nlm.nih.gov/pubmed/26566286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2015.10.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|